190A.T stock led today’s most active list after Chordia Therapeutics Inc. (190A.T) surged 45.22% to JPY 167.00 on 27 Feb 2026 (JPX). Volume exploded to 45,710,300.00 shares versus an average of 972,894.00, driving a gap from the open at JPY 129.00 to a day high of JPY 167.00. The move followed increased intraday interest in the oncology sector and speculative flows into smaller biotech names. We break down why the stock was most active, the valuation backdrop, technical signals, and what Meyka AI’s model projects next

Intraday move and volume: 190A.T stock most active

Chordia Therapeutics (190A.T) finished the Market Closed session at JPY 167.00, up 52.00 points or 45.22% from the previous close of JPY 115.00. The stock logged 45,710,300.00 shares traded, about 47.00 times the average volume, marking it one of the most active names on JPX today.

High intraday volume and a strong price jump point to event-driven or momentum trading rather than a change in long-term fundamentals. Traders should note the day low was JPY 126.00, showing wide intraday range and volatility.

Valuation and key metrics for Chordia Therapeutics (190A.T)

The company trades with market capitalisation of JPY 8,211,071,700.00 and shares outstanding 70,180,100.00. Reported EPS is -26.03, producing a negative PE of -4.49 and a price-to-book of 3.55. Cash per share stands at JPY 33.54 and book value per share at JPY 32.95.

Those ratios show a clinical-stage biotech profile: deep operating losses but large current liquidity relative to liabilities (current ratio 13.43). Investors valuing R&D and trial outcomes should weigh cash runway against binary clinical milestones.

Catalysts, recent news and sector context

No company press release explained today’s spike, so momentum likely reflects sector flows into healthcare and speculative repositioning in small-cap pharma. Japan’s healthcare sector trades at an average PE near 23.62, making Chordia’s negative earnings typical for early-stage biotech.

Broader market headlines may have supported risk appetite; see related market items Investing.com company news 1 and Investing.com company news 2 for recent sector moves that lifted speculative interest.

Technical picture and trading signals for 190A.T stock

Momentum indicators show mixed signals: RSI is 48.64, MACD histogram is -0.76, and ATR is 5.90, indicating neutral momentum with elevated volatility. The stock closed at its session high, but the 50-day average is JPY 115.68 and the 200-day average is JPY 156.48, so price sits above the long-term mean but near it.

Short-term traders should watch support at JPY 126.00 and resistance at the 52-week high JPY 284.00. On-balance volume and stochastic readings warn of possible short-term pullbacks after a large intraday spike.

Risks and opportunities: clinical binary vs liquidity

Key upside comes from successful proof-of-concept results or licensing deals that re-rate small-cap oncology names. A positive clinical readout could push valuations sharply higher given low float and concentrated volume.

Risks are material: negative EPS (-26.03), no revenue per share, and wide historical drawdowns (1Y change -54.65%). Trading volume can amplify moves, increasing liquidity risk for longer-term holders.

Meyka AI rates 190A.T with a score out of 100 and model forecast

Meyka AI rates 190A.T with a score out of 100: 65.53 (Grade B, Suggestion HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a monthly price of JPY 85.73 and a quarterly value near JPY 10.28 based on short-term pattern and liquidity metrics. These figures are model-based projections and not guarantees. Analysts should treat them as scenario inputs rather than firm targets. For direct stock data, view the Meyka page: Chordia Therapeutics 190A.T on Meyka.

Final Thoughts

Chordia Therapeutics (190A.T) was the Market Closed list leader by volume and percentage gain on 27 Feb 2026, finishing at JPY 167.00 with 45,710,300.00 shares traded and a 45.22% move. The jump reflects speculative demand and sector flows rather than a disclosed material update. Valuation metrics show a loss-making clinical-stage biotech with EPS -26.03, negative PE, but strong liquidity (current ratio 13.43) that supports near-term operations. Our practical price targets: conservative JPY 100.00, base JPY 167.00 (current), and upside JPY 250.00 if clinical or licensing catalysts materialize. Meyka AI’s forecast model projects a monthly price of JPY 85.73, implying an estimated downside of -48.69% versus today’s close. Forecasts are model-based projections and not guarantees. Traders should combine clinical event calendars, cash runway checks, and position sizing to manage the stock’s elevated volatility while monitoring sector momentum and any company announcements

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.